Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EMA developing principles on when to 'go broader or narrower' in indication wording

This article was originally published in SRA

Executive Summary

The European Medicines Agency is developing general principles on the wording that drug makers may apply to indicate in which populations their drugs can be used. The "indication wording" initiative will particularly focus on when the population may be broader or narrower compared to the study population investigated in the clinical trials supporting the marketing authorization application for the drug1.

Advertisement
Advertisement
UsernamePublicRestriction

Register